TQB3909 for patients with relapsed or refractory CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new pill called TQB3909 that may offer another option for patients with CLL/SLL who have tried other treatments. It is considered for patients whose cancer has relapsed or not responded to prior therapies, or who could not tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with CLL/SLL and need treatment.
- Your cancer has come back or hasn't improved after at least one prior treatment (like a BTK inhibitor or chemo-immunotherapy).
- You can still swallow pills and have no major organ issues.
- You agree to use contraception if needed and have no other untreated cancers or known central nervous system involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new oral drugs (TQB3909 and TQB3702) together for people with non-Hodgkin lymphoma. It is a first-in-human study, so doctors are looking for the right dose and checking safety. It may be an option if you have not had a stem cell transplant and your lymphoma has not spread to the brain.
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Hear when a new Small Lymphocytic Lymppho trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.